Localized Aeroallergen Exposure in Atopic Dermatitis

Trial details

Who runs it

Fraunhofer-Institute of Toxicology and Experimental Medicine

Trial code

NCT07918586

Record updated

5 November 2026

Original description

This pilot study evaluates skin reactions following localized aeroallergen exposure in adults with atopic dermatitis.Read full original descriptionShow less

Pilot Study to Assess the Localized Aeroallergen Exposure Induced Skin Reaction in Patients With Atopic Dermatitis

This pilot study evaluates skin reactions following localized aeroallergen exposure in adults with atopic dermatitis.

Inclusion: Able and willing to give written informed consent; Male and female subjects, aged 18-65 years. Women will be considered for inclusion if they are:; Not pregnant, as confirmed by pregnancy test (see flow chart), and not nursing; Of non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is pre-menarchial or post-menopausal, with documented proof of hysterectomy or tubal ligation, or meets clinical criteria for menopause and has been amenorrhoeic for more than 1 year prior to the screening visit); Of childbearing potential and using a highly effective method of contraception during the entire study (vasectomised partner, sexual abstinence - the lifestyle of the female should be such that there is complete abstinence from intercourse from two weeks prior to the start of the study until at least 72 hours after the last study visit -, implants, injectables, combined oral contraceptives, hormonal IUDs or double-barrier methods, i.e. any double combination of IUD, condom with spermicidal gel, diaphragm, sponge, and cervical cap); Positive IgE level for grass pollen (Phadia g6, Lieschgras) of at least CAP FEIA class 3 (≥3,50 kU/l) at screening or in previous year; Atopic dermatitis fulfilling the UK criteria of AD; Local SCORAD for erythema domain 1 or 2 in exposed area (cubital fossa / lower arm); Local IGA 1 or 2; Difference of Local SCORAD between both arms ≤ 2; BMI ≥18 and ≤ 40.

Exclusion: Treatment with medication that might interfere with rescue medication for the management of allergic reactions (e.g. beta blocker); Topical (skin) steroid treatment (wash out phase: 2 weeks before day 1); Topical calcineurin inhibitor treatment (wash out phase 2 weeks before day 1); UV radiation treatment (wash out phase 4 weeks before day 1); Systemic immunosuppression treatment (steroids, biologics, e.g. dupilumab, JAK-Inhibitors, cyclosporine, azathioprine, Mycophenolat Mofetil (MMF); wash out phase 3 months, before day 1; Treatment with high dose inhaled corticosteroids; Treatment with antihistamines (wash out phase 1 week before day 1); Acute respiratory infection 2 weeks prior to screening visit; Alcohol or drug abuse within 12 months prior to screening; Participation in another clinical trial 30 days prior to enrollment; History of an acute infection four weeks prior to the informed consent visit; Subject has received previous immunotherapy treatment with any grass pollen allergen within 2 years prior to screening; Subject is receiving ongoing treatment with any specific immunotherapy for other allergies; Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, endocrine disease or pulmonary disease; Positive HIV-1/2Ab, hepatitis B surface antigen (HBsAg) or hepatitis C virus antibodies (HCVAb) test at screening or test not performed; Any clinically relevant abnormal findings in physical examination, clinical chemistry, hematology, vital signs at screening visit, which, in the opinion of the investigator, may either put the subject at risk because of participation in the study or may influence the results of the study, or the subject's ability to participate in the study; Unstable AD during Screening (SCORAD difference of >15 points from Visit 1 to Visit 2); Diastolic blood pressure above 95 mmHg; Regular daily consumption of more than 1 liter of usual beer or the equivalent quantity of approximately 40 g of alcohol in another form; There is a risk of non-compliance with study procedures; Suspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study.

ClinicalTrials.gov NCT07918586